Neuro Startup Makes Debut With $20.9M From Novo, Johnson & Johnson Post author:Sam Post published:February 8, 2018 Post category:BioPharma Syndesi will work to modulate the synaptic vesicle protein SV2A. Source: BioSpace You Might Also Like Provectus Announces Extension Of Rights Offering Due To Receipt Of Unsolicited Investment Proposals To Invest In March 5, 2017 3 Biotechs With Make-or-Break Trial Results, FDA Meetings Coming Soon September 21, 2017 Questions Arise Over the World's Richest Doctor's 'Breakthrough' Cancer Therapy Promo Videos March 27, 2017
Provectus Announces Extension Of Rights Offering Due To Receipt Of Unsolicited Investment Proposals To Invest In March 5, 2017
Questions Arise Over the World's Richest Doctor's 'Breakthrough' Cancer Therapy Promo Videos March 27, 2017
